References
- Chan A C, Iwashima M, Turck C W, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR ζ chain. Cell 1992; 71: 649–662
- Guillaume N, Alleaume C, Munfus D, Capiod J C, Touati G, Pautard B, et al. ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica 2005; 90: 899–905
- Nolz J C, Tschumper R C, Pittner B T, Darce J R, Kay N E, Jelinek D F. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005; 19: 1018–1024
- Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951
- Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl Med J 2004; 351: 893–901
- Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
- Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041
- Castro J E, Prada C E, Loria O, Kamal A, Chen L, Burrows F J, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005; 106: 2506–2512
- Richardson S J, Matthews C, Catherwood M A, Alexander H D, Carey B S, Farrugia J, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B cell chronic lymphocytic leukemia (B-CLL). Blood 2005; 107: 3584–3592
- Maynadie M, Matutes E, Catovsky D. Quantification of P-glycoprotein in chronic lymphocytic leukemia by flow cytometry. Leuk Res 1997; 21: 825–831
- Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750–758
- Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, et al. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Haematologica 1997; 82: 143–147
- Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia. Eur J Haematol 2004; 73: 407–411
- Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
- Svoboda-Beusan I, Kusec R, Bendelja K, Tudoric-Ghemo I, Jaksic B, Pejsa V, et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000; 85: 1261–1267